Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 89 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,199 | -19.7% | 220 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $1,494 | +35.6% | 220 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,102 | +2.6% | 220 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $1,074 | -89.3% | 220 | -69.4% | 0.00% | -88.9% |
| Q3 2022 | $10,000 | -9.1% | 720 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $11,000 | +22.2% | 720 | 0.0% | 0.01% | +50.0% |
| Q1 2022 | $9,000 | -35.7% | 720 | -17.2% | 0.01% | -33.3% |
| Q4 2021 | $14,000 | -54.8% | 870 | -21.1% | 0.01% | -60.9% |
| Q3 2021 | $31,000 | -27.9% | 1,103 | -13.9% | 0.02% | -28.1% |
| Q2 2021 | $43,000 | +290.9% | 1,281 | +265.0% | 0.03% | +255.6% |
| Q1 2021 | $11,000 | -42.1% | 351 | -7.9% | 0.01% | -43.8% |
| Q4 2020 | $19,000 | -78.4% | 381 | -83.3% | 0.02% | -79.7% |
| Q3 2020 | $88,000 | +780.0% | 2,280 | +854.0% | 0.08% | +618.2% |
| Q2 2020 | $10,000 | – | 239 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $1,041,909 | 4.24% |
| Sofinnova Investments, Inc. | 2,194,278 | $11,958,815 | 0.75% |
| DENALI ADVISORS LLC | 85,900 | $468,155 | 0.16% |
| Polar Capital Holdings Plc | 2,103,298 | $11,462,974 | 0.08% |
| Soleus Capital Management, L.P. | 157,182 | $856,642 | 0.08% |
| GSA CAPITAL PARTNERS LLP | 137,299 | $748 | 0.06% |
| Caligan Partners LP | 23,321 | $127,099 | 0.06% |
| Corton Capital Inc. | 12,244 | $66,730 | 0.03% |
| RICE HALL JAMES & ASSOCIATES, LLC | 91,249 | $497,307 | 0.03% |
| CIM INVESTMENT MANAGEMENT INC | 15,313 | $83,456 | 0.03% |